Cover Image

Biologics targeting interleukin (IL)‐23 and the risk of cardiovascular events: Where are we?

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	F. Poizeau, H. Ait‐Oufella, H. Bachelez
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Journal of the European Academy of Dermatology and Venereology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Moles and melanomas on tattoos: Where we are in 2025
by: Nicolas Kluger
Published: (2025)

The role of interleukin‐36 in health and disease states
by: Kazumitsu Sugiura, et al.
Published: (2024)

Single‐cell transcriptomic analysis of GPP patients treated with IL‐12/23 or IL‐17A blockade
by: Soyoung Jeong, et al.
Published: (2025)

Could the IL ‐17 cytokine family be a promising target for the treatment of palmoplantar pustulosis?
by: Ulrich Mrowietz, et al.
Published: (2026)

TNF inhibitors and cardiovascular risk: Friend or foe?
by: Joel M. Gelfand, et al.
Published: (2024)

Switching within the class of IL‐23 inhibitors for the treatment of psoriasis: A systematic review
by: Ioannis‐Alexios Koumprentziotis, et al.
Published: (2025)

Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies
by: H. Bachelez, et al.
Published: (2024)

Differential risks of venous thromboembolic events in pemphigus and pemphigoid diseases
by: Maren E. Buenning, et al.
Published: (2025)

Anti‐IL‐23 therapy for the treatment of moderate‐to‐severe inverse psoriasis: A 52‐week multicenter study
by: Joan Ceravalls, et al.
Published: (2024)

GLP ‐ 1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study
by: Elaine J. Ma, et al.
Published: (2026)

Generalized pustular psoriasis: A nationwide population‐based study using the National Health Data System in France
by: Manuelle Viguier, et al.
Published: (2024)

Effect of GLP‐1RA on mortality and cardiovascular risk in adults with psoriasis and type 2 diabetes
by: Claire Lin, et al.
Published: (2026)

Top weapons in skin aging and actives to target the consequences of skin cell senescence
by: Z. Draelos, et al.
Published: (2024)

Skin lymphomas in childhood: We only see what we know, we only know what we see
by: Iris Wohlmuth
Published: (2024)

GLP‐1RAs and cardiovascular risk in HS: concerns about follow‐up time and effect estimates
by: Beata Jastrząb, et al.
Published: (2025)

GLP ‐ 1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real‐world cohort study
by: Peichi P. Chou, et al.
Published: (2025)

Biologic therapies and psoriatic arthritis risk in psoriasis: A systematic review and meta‐analysis
by: Li Yang, et al.
Published: (2026)

Unmasking prurigo nodularis endotypes: Dominant role of IL 31 dysregulation
by: Sonja Ständer, et al.
Published: (2025)

Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis
by: N. Á. Galajda, et al.
Published: (2024)

Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
by: Bruce Strober, et al.
Published: (2024)

Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression: Recommendations from a SPIN‐FRT expert consensus
by: T. Torres, et al.
Published: (2024)

Increased risk of cutaneous squamous cell carcinoma in hidradenitis suppurativa: A matched cohort study
by: Matthew H. Lanehart, et al.
Published: (2025)

Why we choose to publish on personalized medicine in dermatology
by: Jo Lambert, et al.
Published: (2026)

Management of IL ‐17 inhibitors‐induced paradoxical eczema in patients with plaque psoriasis
by: Paolo Gisondi, et al.
Published: (2025)

How can we improve patient care in hidradenitis suppurativa?
by: Maria Polina Konstantinou, et al.
Published: (2026)

Gender Equity and Academic Dermatology: Are we giving the right advice?
by: Alexa B. Kimball
Published: (2024)

Inclusive by design: Why we must rethink generative AI in dermatology
by: O. E. Dadzie, et al.
Published: (2025)

Associations of skin cancer, dermatitis and risk factors for skin conditions with epigenetic aging
by: Raj P. Fadadu, et al.
Published: (2026)

T helper and IL ‐20 cytokine signatures distinguish atopic dermatitis from contact dermatitis subtypes
by: Axel De Greef, et al.
Published: (2025)

Iris pattern as a marker of skin cancer risk
by: F. Ricci, et al.
Published: (2024)

Sodium intake: An emerging dietary target in psoriasis
by: Stephen Chu‐Sung Hu, et al.
Published: (2025)

Comparison of artificial intelligence smartphone applications for skin cancer risk stratification of pigmented lesions: An observational study
by: Lara Milliken, et al.
Published: (2024)

Netherton syndrome and papillomatous lesions—Should we perform human papilloma virus vaccination?
by: Regina Fölster‐Holst, et al.
Published: (2024)

Generalized pustular psoriasis induced by an intraductal pancreatic tumour producing IL ‐36γ: A case report
by: Misa Ishida, et al.
Published: (2026)

IL‐6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study
by: A. Reimer‐Taschenbrecker, et al.
Published: (2024)

Recibokibart, an anti‐IL‐36 receptor monoclonal antibody, for treating generalized pustular psoriasis: Phase 1b trial
by: Qiaoxia Qian, et al.
Published: (2025)

Are we missing Mpox cases? Changes in clade IIb clinical phenotype in the post‐vaccination era
by: Taiana Silva Carvalho, et al.
Published: (2025)

Impact of methotrexate administration route on drug survival in psoriasis: Results from PSOBIOTEQ
by: Chloé Paris, et al.
Published: (2025)

Beyond skin: Integrating the cardiovascular impact of psoriasis therapies into disease management
by: Tiago Torres
Published: (2025)

Can we trust AI for acne advice: A double‐blind performance comparison with NICE guidelines
by: Xufei Luo, et al.
Published: (2025)